OpenEvidence AI healthcare has become one of the most closely watched private companies in medical technology after reports that it raised $250 million at a $15 billion valuation. The reports, which appeared in late September 2026 and were based on unnamed sources, say the figure is 25% above the $12 billion valuation set in January 2026. We could not find a company confirmation in the material we reviewed. This report separates what is reported from what the company says, explains what the usage and revenue numbers do and do not show, and lists what to watch. It is general information and not investment or medical advice.
OpenEvidence AI healthcare: key takeaways
- Reported, not confirmed: a $250 million round at a $15 billion valuation, up from $12 billion in January 2026.
- One report names Andreessen Horowitz as lead investor, with hospital systems also taking part; we found that in a single source.
- Company-stated usage: more than 40% of US physicians, with about 18 million clinical consultations by verified doctors in December 2025, according to one report.
- Revenue figures are estimates from third parties and differ by date.
- Reports of acquisition interest are unconfirmed, and no offer has been disclosed.
What is reported about the OpenEvidence AI healthcare round
According to the reports, the $250 million round was quietly closed and values the company at $15 billion. One account says the founders are fielding acquisition interest and may be open to a sale instead of an initial public offering. Another says the investors include hospital systems. Neither the round, the valuation nor the sale talk was described as confirmed by the company in the sources we saw, so readers should treat them as reports. The company’s own site, OpenEvidence, describes its product but did not, in what we reviewed, address the funding.
The valuation history of OpenEvidence AI healthcare
The reports describe a steep climb. One puts the valuation at roughly $6 billion in October 2025. A funding of $250 million at $12 billion followed in January 2026, which healthcare press at the time described as a doubling. The reported $15 billion would be the third step in about a year. Earlier reports in July spoke of a possible raise at a higher figure of $20 billion, and how that relates to the $15 billion now reported is unclear to us. Valuations in private rounds reflect negotiated terms and are not market prices.
What OpenEvidence says about usage
The usage figures reported are company-stated and come from one report. They say more than 40% of US physicians use the service, that verified doctors held about 18 million clinical consultations in December 2025, and that it is used across more than 10,000 hospitals and medical centres. We cannot independently verify these numbers. Counting methods matter: a physician who logs in once a month counts as a user, and consultations are not the same as clinical decisions. They are best read as signs of adoption and not of outcomes.
OpenEvidence AI healthcare: revenue and the business model
The service is reported to be free for physicians and to earn money from advertising aimed at medical professionals and other commercial relationships. One report says annualised revenue passed $100 million by January 2026. Another cites a third-party research firm’s estimate of about $300 million annualised by mid-2026, which is an outside estimate and not company data. Our calculation, using that estimate, puts the reported valuation at about 50 times annualised revenue. That multiple is high and rests on a figure the company has not confirmed.
Why investors may value OpenEvidence AI healthcare
This section is our analysis. A tool that large numbers of doctors open daily has a valuable audience, and advertisers pay for access to clinicians. Partnerships that put the product inside electronic health record workflows could make it harder to replace. One report says Memorial Sloan Kettering Cancer Center announced in September that it will integrate the product into Epic-based workflows and add an oncology knowledge base. These are reasons for investor interest, not evidence that the product improves care.
What the valuation does not show about OpenEvidence AI healthcare
A valuation measures what investors expect to earn, not whether answers are accurate or safe. The reports we reviewed give no data on error rates, on how often clinicians change decisions because of answers, or on patient outcomes. Medical AI tools are usually expected to link answers to sources so users can check them, and the product is reported to do this, but the quality of retrieval and summarisation still needs independent testing. The FDA guidance on clinical decision support software sets out when software that supports clinical decisions may be regulated as a device.
What is not disclosed about OpenEvidence AI healthcare
- Company confirmation of the round, the valuation and the investors.
- Audited revenue and the share from advertising.
- Independent accuracy testing of the product’s answers.
- The terms of any acquisition interest.
Risks and caveats on OpenEvidence AI healthcare
- Funding and sale reports rely on unnamed sources and are unconfirmed.
- Usage and revenue figures differ by source and date.
- An advertising-supported model raises questions about independence that readers may wish to ask about.
- This is news reporting, not investment or medical advice.
In our assessment, the OpenEvidence AI healthcare story shows how fast investors are paying for physician-facing AI, but a reported valuation is not proof of clinical quality, and the evidence that matters most, independent accuracy and outcome data, has not been published in what we reviewed. See also Anthropic and OpenEvidence Launch Free Medical AI for Doctors Across About 100 Countries. More in our healthcare IT coverage.
What to watch next on OpenEvidence AI healthcare
- Any company confirmation or denial of the round and sale talk.
- Independent studies of answer accuracy; see also the WHO guidance on the ethics and governance of artificial intelligence for health.
- New hospital and health-system partnerships.
Frequently asked questions
How much is OpenEvidence reportedly worth?
Reports say $15 billion after a $250 million round, up from $12 billion in January 2026; the company has not confirmed it in what we saw.
What does OpenEvidence do?
It is an AI-powered medical search tool for physicians that links answers to sources, according to the reports.
Is OpenEvidence for sale?
Reports say it is fielding acquisition interest; no offer has been disclosed and the company may remain independent.
How we reported this: we relied on published reports from September 2026 and the company website, and we did not see a company statement on the funding. Company claims and our analysis are labelled. Last updated: 22 October 2026. This article is news reporting and not investment or medical advice.